Roca J, Grau M, Balasch J
Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401.
The effect of pirozadil, a new hypolipidemic agent, on cerebral blood flow was tested in anesthetized dogs and compared to that of two other hypolipidemic/antiatherogenic agents, nicotinic acid and pyridinol carbamate. Nicardipine and papaverine, vasodilator drugs, were used as controls. Measurement of cerebral blood flow was performed by attaching an electromagnetic blood flow transducer to the vertebral artery of the anesthetized dog. Pirozadil's effect on increasing cerebral blood flow was almost equal to that of papaverine, less than that of nicardipine and much greater than that of the other hypolipidemic/antiatherogenic drugs, nicotinic acid and pyridinol carbamate. Pirozadil was also shown to significantly diminish vascular cerebral resistance to a much greater degree than nicotinic acid and pyridinol carbamate.
在麻醉犬身上测试了新型降血脂药物吡罗扎地对脑血流量的影响，并将其与另外两种降血脂/抗动脉粥样硬化药物烟酸和卡巴匹林钙进行比较。血管扩张剂尼卡地平和罂粟碱用作对照。通过将电磁血流传感器连接到麻醉犬的椎动脉来测量脑血流量。吡罗扎地增加脑血流量的作用几乎与罂粟碱相当，小于尼卡地平，且远大于其他降血脂/抗动脉粥样硬化药物烟酸和卡巴匹林钙。吡罗扎地还显示出比烟酸和卡巴匹林钙更显著地降低脑血管阻力。
